Features of diagnosis and treatment in patients with ST-segment elevation myocardial infarction and SARS-CoV-2 infection

Read full text
Authors: Vladislav E. Ispavskii, Изможерова Надежда Владимировна, A. A. Popov, Andrey I. Tsvetkov, S. V. Kozlov, Valerii Sergeevich Ermakov, В. Н. Кравчук
Cited by: 0
References: 8

Abstract

Objectives . To evaluate clinical, laboratory, and instrumental features of diagnosis and treatment in patients with ST-segment elevation myocardial infarction (STEMI) and SARS-CoV-2 infection (COVID-19). Material and methods . The retrospective case-control study included 114 patients (57 pairs adjusted by gender, age, comorbidity and diagnosis of STEMI) who underwent coronary angiography (CAG). According to the temporary routing regulations for the pandemic in the Sverdlovsk region, in each pair one of the patients had been hospitalized with COVID-19 (group 1) at the Central City Hospital, Verchnya Pyshma, and the other person without COVID-19 (group 2) had been admitted to LLC Medical Association «Novaya Bolnica», Yekaterinburg. July to December 2020 medical records data were processed. Results . Patients with COVID-19 underwent PCI significantly later from the onset of symptoms, 607.0 (340.0–870.0) minutes versus 350.0 (190.0–450.0), p < 0.001. There were no difference in anatomy and the number of affected coronary arteries between the study groups. Massive coronary thrombosis was equally common in both groups, both with COVID-19 in 57.9% of cases and without COVID-19 in 56.1%, p = 0.849. Stenting attempts in the COVID-19 group were slightly less frequent and performed in 89.5% cases, while in patients without COVID-19 stenting occurred in 96.5% cases, p = 0.232. The optimal stenting result as TIMI 3 blood flow was obtained slightly less in the NCVI group: 94.2% versus 98.2% in patients without COVID-19, p = 0.067. COVID-19 positive subjects with STEMI required more days of hospitalization: 13.0 (10.0–18.0) versus 8.0 (8.0–8.0) in the group without COVID-19, p < 0.001. Conclusions . The manifestations of an infectious disease in cases of COVID-19 and STEMI comorbidity negatively affected the time from the onset of symptoms to the initiation of reperfusion therapy and caused a significantly longer duration of hospitalization. At the same time, timely routing decisions at the regional level to ensure the availability of primary PCI for all patients with STEMI, regardless of the presence of an infectious disease, allowed acceptable intervention results to be achieved in the vast majority of patients in both groups.

Fields of Study & Subjects

Acute Myocardial Infarction Research COVID-19 Clinical Research Studies COVID-19 and healthcare impacts

Publication details

Journal / source
Clinical Medicine (Russian Journal)
Volume
103
Issue
10-11
Pages
744–752
Publication date
14 February 2026
Language
EN